Jacobs Levy Equity Management Inc. Has $7.63 Million Stock Position in Arcus Biosciences, Inc. $RCUS

Jacobs Levy Equity Management Inc. grew its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 108.9% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 972,157 shares of the company's stock after buying an additional 506,853 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.92% of Arcus Biosciences worth $7,631,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Arcus Biosciences by 2.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock worth $506,000 after buying an additional 833 shares during the last quarter. Maryland State Retirement & Pension System grew its stake in shares of Arcus Biosciences by 10.9% during the first quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company's stock worth $159,000 after buying an additional 1,986 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Arcus Biosciences by 7.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,748 shares of the company's stock worth $281,000 after buying an additional 2,524 shares during the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Arcus Biosciences by 21.3% during the first quarter. Oregon Public Employees Retirement Fund now owns 15,381 shares of the company's stock worth $121,000 after buying an additional 2,700 shares during the last quarter. Finally, Amalgamated Bank grew its stake in shares of Arcus Biosciences by 18.4% during the first quarter. Amalgamated Bank now owns 18,797 shares of the company's stock worth $148,000 after buying an additional 2,922 shares during the last quarter. Institutional investors own 92.89% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wall Street Zen raised shares of Arcus Biosciences from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. Wells Fargo & Company reduced their price objective on shares of Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $21.14.

Arcus Biosciences Stock Performance

RCUS stock remained flat at $11.50 during midday trading on Friday. 711,202 shares of the company traded hands, compared to its average volume of 721,220. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -3.63 and a beta of 0.83. The company has a current ratio of 4.50, a quick ratio of 4.50 and a debt-to-equity ratio of 0.18. Arcus Biosciences, Inc. has a 1-year low of $6.50 and a 1-year high of $18.98. The company's fifty day moving average price is $10.02 and its two-hundred day moving average price is $9.16.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.03. The business had revenue of $160.00 million for the quarter, compared to analyst estimates of $32.86 million. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. Arcus Biosciences's revenue for the quarter was up 310.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.02) earnings per share. On average, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.